Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs.Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 13, 2015 | Series C | $65M | 1 | — | — | Detail |
Dec 2, 2014 | Series B | $42.50M | 1 | — | — | Detail |
Jul 18, 2013 | Series A | $30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | — | Series C |